EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Clozapine and norclozapine pharmacokinetic interaction with pantoprazole

Orwa Albitar iD, Sabariah Noor Harun, Siti Maisharah Sheikh Ghadzi

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70450 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Orwa Albitar und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia. Hauptthemen laut MEDLINE: Clozapine, Antipsychotic Agents, 2-Pyridinylmethylsulfinylbenzimidazoles, Proton Pump Inhibitors. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Universiti Sains Malaysia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Clozapine is the first‐line treatment for resistant schizophrenia. However, clozapine concentrations should be monitored, especially in the case of drug–drug interactions. The current work aimed to assess the clozapine interaction with pantoprazole.

Methods

This was a randomized open‐label crossover study involving 12 healthy volunteers. The participants received a single dose of clozapine 12.5 mg in the two phases of the study alone or following five daily doses of pantoprazole 40 mg to be started 4 days before the clozapine dose, separated by a minimum of 2‐week washout period. 144 samples were collected at 30 min, 1, 2, 3, 5 and 8 h following a single dose of clozapine 12.5 mg. The clozapine and norclozapine concentrations were determined using a validated HPLC‐UV protocol.

Results

The pantoprazole treatment group had 8.7% lower clozapine bioavailability and lower maximum concentration (C max ) and area under the curve (AUC (0‐8) ) by 8.9% (95% confidence intervals [95% CI], 6.7%–11.0%) and 9% (95% CI, 7.2–10.8%), respectively, as well as significantly lower norclozapine C max and AUC (0–8) by 8.2% (95% CI, 6.3%–10.2%) and 8.5% (95% CI, 7.3%–9.7%), respectively. However, no significant difference was found in the norclozapine AUC (0–8) to clozapine AUC (0–8) ratio between the two treatment groups.

Conclusions

The concurrent intake of pantoprazole decreased the clozapine and norclozapine exposure, which was explained by the pantoprazole's impact on gastric acidity and clozapine absorption rather than on metabolizing enzymes. The interaction was not clinically relevant at low doses; however, clinicians should consider concomitant acid‐reducing agents when interpreting clozapine therapeutic drug monitoring results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClozapineAntipsychotic Agents2-PyridinylmethylsulfinylbenzimidazolesProton Pump InhibitorsHumansDrug InteractionsPantoprazoleCross-Over StudiesMaleAdultFemaleYoung AdultArea Under CurveBiological AvailabilityChromatography, High Pressure Liquid

Stichwörter der Autor:innen

NONMEMdrug interactionsdrug metabolismpharmacokineticspsychopharmacology

Substanzen

ClozapinePantoprazoleAntipsychotic Agents2-PyridinylmethylsulfinylbenzimidazolesnorclozapineProton Pump Inhibitors

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.

ORCID-Profile: Orwa Albitar

Förderung

  • Universiti Sains Malaysia

Zitieren

APA

Albitar, O., Harun, S. N., & Ghadzi, S. M. S. (2026). Clozapine and norclozapine pharmacokinetic interaction with pantoprazole. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70450

Vancouver

Albitar O, Harun SN, Ghadzi SMS. Clozapine and norclozapine pharmacokinetic interaction with pantoprazole. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70450

BibTeX
@article{Albitar2026,
  author = {Albitar, Orwa and Harun, Sabariah Noor and Ghadzi, Siti Maisharah Sheikh},
  title = {Clozapine and norclozapine pharmacokinetic interaction with pantoprazole},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70450}
}
Kostenlos starten →